The therapeutic efficacy of edaravone in extensively burned rats.
BACKGROUND
Extensive burn injury leads to production of free radicals subsequent to massive fluid resuscitation, which in turn increases the risk of acute lung injury. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, is clinically effective in improving the prognosis after cerebral infarction. However, the effect of edaravone against extensive burn injury has not been tested. Objected To evaluate whether edaravone can reduce free radical precursors in a 30% burn model in rats.


METHODS
Prospective, randomized controlled experiment.


METHODS
Animal basic science laboratory.


METHODS
Male Wistar rats weighing 200 to 220 g.


METHODS
All rats (n = 10) were given a 30% full-thickness burn according to the Walker and Mason method. Immediately after the burn, edaravone was injected into the rats (n = 5) intraperitoneally at a dose of 9 mg/kg. One hour after burn injury, blood and tissue samples were collected to analyze free radical changes of serum and tissue malondialdehyde (MDA) and xanthine oxidase (XOD) and lung white blood cells.


RESULTS
Statistical significance was found between nontreatment and edaravone treatment relative to serum MDA (mean +/- SD, 2.50 +/- 0.54 vs 1.74 +/- 0.29 nmol/mL), serum XOD (mean +/- SD, 5.04 +/- 1.67 vs 2.26 +/- 0.83 U/L), tissue MDA (mean +/- SD, 1268.7 +/- 289.9 vs 569.1 +/- 135.9 nmol/mg protein), tissue XOD (mean +/- SD, 256.3 +/- 58.1 vs 50.96 +/- 19.60 mU/g tissue), lung white blood cells (mean +/- SD, 3088 +/- 1144 vs 1542 +/- 575 mU/g tissue), and lung XOD (mean +/- SD, 428.3 +/- 210.5 vs 81.8 +/- 36.0 nmol/mg protein).


CONCLUSIONS
Edaravone treatment induces significant reduction of free radical precursors and their metabolites compared with controls in burn rats. This suggests that edaravone could be helpful in the clinical treatment of large burns.
Koizumi
Takeo
T
Department of Emergency and Critical Care Medicine, Medical School of Kyorin University, Tokyo, Japan. take99051@hotmail.com
Tanaka
Hideharu
H
Sakaki
Seiki
S
Shimazaki
Shuji
S
D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002056:Burns / Q000188:drug therapy*; D004195:Disease Models, Animal; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use*; D005609:Free Radicals; D008168:Lung / Q000737:chemistry; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D011446:Prospective Studies; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014969:Xanthine Oxidase / Q000097:blood
D016166:Free Radical Scavengers; D005609:Free Radicals; D008315:Malondialdehyde; D014969:Xanthine Oxidase; D000077553:Edaravone; D000983:Antipyrine